Archive - September 2018
Pfizer, Merck immunotherapy combo delays kidney cancer progression
Novartis eye unit Alcon moves from Texas to Geneva
Health secretary’s ‘rip off’ remarks anger UK pharma
Takeda rebels take aim at Shire acquisition
Dismay as NICE rejects Roche’s MS drug Ocrevus
Four new medicines available via NHS Scotland
WPP stays in familiar hands with new chief exec
EC green-lights MSD’s Keytruda combo for lung cancer